DIANTHUS THERAPEUTICS INC (DNTH:NASDAQ)
$82.09 5.64 (7.3774%)
Analysed DIANTHUS THERAPEUTICS INC (DNTH:NASDAQ) News Sources
Dianthus Therapeutics to Participate in Two Investor Conferences
26-05-2026
yahoo.com
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02-06-2026
yahoo.com
Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier
03-06-2026
yahoo.com
Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline
05-06-2026
yahoo.com
Will Orphan Drug Status And Advancing Autoimmune Pipeline Change Dianthus Therapeutics' (DNTH) Narrative
10-06-2026
yahoo.com
Stocks Fall on Weakness in Tech and Trucking Companies
10-06-2026
barchart.com
Stocks Resume Decline as Chipmakers and AI Companies Fall
10-06-2026
barchart.com
Stocks Settle Sharply Lower on Escalating Middle East Tensions
10-06-2026
barchart.com
Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit
10-06-2026
yahoo.com
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results
12-06-2026
stocktwits.com
What is the current price of DIANTHUS THERAPEUTICS INC (DNTH:NASDAQ)?
The current price of DIANTHUS THERAPEUTICS INC (DNTH:NASDAQ) is $82.09.
DIANTHUS THERAPEUTICS INC (DNTH:NASDAQ) absolute price change since previous trading day?
The absolute price change of DIANTHUS THERAPEUTICS INC (DNTH:NASDAQ) since the previous trading day is $5.64.
DIANTHUS THERAPEUTICS INC (DNTH:NASDAQ) percentage price change since previous trading day?
The percentage price change of DIANTHUS THERAPEUTICS INC (DNTH:NASDAQ) since the previous trading day is 7.3774%.
What is the most recent average sentiment score for DIANTHUS THERAPEUTICS INC (DNTH:NASDAQ)?
The most recent average sentiment score for DIANTHUS THERAPEUTICS INC (DNTH:NASDAQ) is 52 out of 100.
What is the most recent average sentiment for DIANTHUS THERAPEUTICS INC (DNTH:NASDAQ)?
The most recent sentiment for DIANTHUS THERAPEUTICS INC (DNTH:NASDAQ) is .
SEC-8K** Filing Available For DIANTHUS THERAPEUTICS INC (DNTH:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.